Last updated: March 23, 2026
What Is NDC 00574-0293?
NDC 00574-0293 corresponds to Aflibercept (Eylea), a prescribed biologic used primarily for treating various retinal diseases, including neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusions.
Market Scope
The global retinal disease treatment market was valued at approximately USD 4.8 billion in 2022 and is projected to grow to USD 8.2 billion by 2027, at a compound annual growth rate (CAGR) of 11.3% (MarketsandMarkets, 2022[1]). Aflibercept accounts for roughly 25% of this market, with key competitors including Ranibizumab (Lucentis) and Bevacizumab (Avastin).
Market Drivers
- Increasing prevalence of AMD, DME, and retinal vein occlusions.
- Aging populations globally.
- Advancements in drug delivery systems.
- Clinical evidence supporting efficacy over prior therapies.
Market Constraints
- High drug costs.
- Patent expirations leading to biosimilar entry.
- Access and reimbursement challenges.
Price Analysis
List Price and Reimbursement
- Average wholesale price (AWP) for Aflibercept is approximately USD 1,850 per dose (per 2 mg/0.05 mL vial).
- The actual reimbursed price varies based on payer negotiations, pharmacy discounts, and regional regulations.
- In the US, Medicare reimbursement typically covers around USD 1,200 per dose.
Competitive Pricing
| Product |
Dose Price (USD) |
Indications |
Patent Status |
| Aflibercept (Eylea) |
~$1,850–$2,000 |
AMD, DME, retinal vein occlusion |
Patent until 2023-2024 |
| Ranibizumab (Lucentis) |
~$1,950 |
Similar ophthalmic indications |
Patent until 2023-2025 |
| Brolucizumab (Beovu) |
~$1,900–$2,100 |
AMD |
Patent until 2025 |
| Biosimilars (pending approval) |
~$1,200–$1,500 |
Similar indications |
Patent expiry 2023–2024 |
Biosimilar versions of aflibercept are expected to undercut branded prices by up to 30%, pending regulatory approval (FDA, EMA).
Price Projections
Short-Term (2023–2025)
- Market consolidation may lead to price stabilization or slight decrease due to biosimilar competition.
- Price per dose expected to decline by approximately 10–15%, reaching USD 1,600–USD 1,700 in the US.
- Reimbursement pressures likely to persist, influencing net prices.
Medium to Long-Term (2026–2030)
- Biosimilar penetration could reduce prices by 25–30% below current levels.
- Competitive market dynamics and potential policy shifts could further impact pricing.
- Innovation in drug delivery (e.g., sustained-release formulations) might influence treatment regimens and pricing models.
Regional Variations
| Region |
Average Price per Dose (USD) |
Key Factors |
| United States |
~$1,200–$1,850 |
Reimbursement, rebates, brand vs. biosimilars |
| Europe |
~$1,000–$1,700 |
Price regulation, reimbursement systems |
| Asia-Pacific |
~$800–$1,500 |
Lower drug tariffs, emerging biosilimar market |
Strategic Considerations
- Patent expirations present opportunities for biosimilar entrants.
- Price sensitivity varies among regions; emerging markets favor lower-cost options.
- Payers favor biosimilars, pressuring list prices for branded drugs.
- Ongoing clinical trials exploring extended dosing intervals could impact treatment costs.
Key Market Trends
- Biosimilars expected to account for 35% of aflibercept prescriptions globally by 2027.
- Combined utilization of aflibercept and other anti-VEGF agents depends on clinical outcomes and formulary placements.
- Innovations such as port delivery systems and long-acting formulations may modify future pricing.
Final Summary
The primary driver shaping aflibercept market prices is patent expiry, with biosimilar entry forecasted to reduce costs significantly starting around 2023–2024. Presently, list prices are around USD 1,850 per dose in the US, with actual reimbursement often lower. Prices are expected to decline gradually over the next five years, with larger reductions anticipated when biosimilar products attain market approval and adoption.
Key Takeaways
- NDC 00574-0293 (Aflibercept) is a leading treatment for retinal diseases, with a global market valued at USD 4.8 billion (2022).
- Current list prices in the US are approximately USD 1,850 per dose.
- Patent expirations in 2023–2024 are likely to facilitate biosimilar competition, bringing prices down by 25–30% over the next five years.
- Price sensitivity varies regionally, with lower prices in emerging markets.
- Market growth will continue driven by increasing retinal disease prevalence and advances in delivery systems.
FAQs
Q1: When do patents for aflibercept expire?
Patents expire in 2023 in the US and Europe, opening the market for biosimilars.
Q2: What is the projected impact of biosimilars on aflibercept prices?
Biosimilars are expected to reduce prices by 25–30% upon market entry.
Q3: How does the reimbursement landscape affect net prices?
Reimbursements often lower the effective price paid by payers, with US Medicare covering about USD 1,200 per dose.
Q4: Are biosimilars approved in major markets?
Yes, biosimilars for aflibercept are in regulatory review or approved in some jurisdictions but face market adoption hurdles.
Q5: What factors influence future price trends?
Patent expirations, biosimilar adoption rates, clinical innovation, and regional pricing policies will shape future prices.
References
[1] MarketsandMarkets. (2022). Retinal Diseases Market by Disease, Treatment, and Region: Global Forecast to 2027.
